BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Offering Cost-Effective, Efficient BCI Solutions

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, has created two FDA-cleared products (the NeuroCap(TM) and NeuroEEG(TM)) that are nothing like other brain-computer interface (“BCI”) solutions in the market. It has been observed that “data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs (electroencephalograms),” notes a recent article. “Many of the BCIs on the market are not gelled so that the consumer can easily fit the product themselves. They have far fewer electrodes and are designed for the ease of the consumer rather than the researcher. Brain Scientific is different… the company provides a cost-efficient, pre-gelled, disposable and wireless solution that provides the same signal quality as the traditional wired EEG.”

To view the full article, visit https://ibn.fm/vd9sq

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent…

11 hours ago

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the…

13 hours ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet…

16 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences

Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with the Brush and Key Foundation, announced the publication…

3 days ago

BioMedNewsBreaks — Volition Solves Liquid Biopsy’s “Needle in a Haystack” Problem; Achieves 180-fold (18,000%) Enrichment

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced the preprint release of…

7 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in…

1 week ago